Brokerage firm Stifel Nicolaus Upgrades its rating on Puma Biotechnology Inc(NYSE:PBYI). The shares have been rated Buy. Previously, the analysts had a Hold rating on the shares. The rating by Stifel Nicolaus was issued on Sep 21, 2016.
Puma Biotechnology Inc (PBYI) made into the market gainers list on Tuesdays trading session with the shares advancing 10.53% or 6.21 points. Due to strong positive momentum, the stock ended at $65.16, which is also near the day’s high of $68. The stock began the session at $64.42 and the volume stood at 34,80,277 shares. The 52-week high of the shares is $103.62 and the 52 week low is $19.74. The company has a current market capitalization of $2,117 M and it has 3,24,93,092 shares in outstanding.
Puma Biotechnology Inc(PBYI) last announced its earnings results on Aug 9, 2016 for Fiscal Year 2016 and Q2.Earnings per share were $-1.17. Analysts had estimated an EPS of $-2.18.
Several Insider Transactions has been reported to the SEC. On Jul 8, 2015, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 3,000 shares at $110.03 per share price.
Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the acquisition development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive breast cancer and patients with non-small cell lung cancer breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1 HER2 and HER4.